Chembio Diagnostics, Inc. Sustainability Profile
Chembio Diagnostics, Inc., a leading player in the diagnostics industry, is headquartered in the United States and operates across various regions globally. Founded in 1985, the company has established itself as a pioneer in the development of innovative point-of-care testing solutions, particularly in infectious disease diagnostics. Chembio's core products include rapid tests for diseases such as HIV, syphilis, and malaria, distinguished by their accuracy and speed. The company’s unique dual-path technology enhances test performance, setting it apart in a competitive market. With a commitment to improving patient outcomes, Chembio has achieved significant milestones, including partnerships with global health organisations. Recognised for its contributions to public health, Chembio Diagnostics continues to strengthen its market position through ongoing research and development, ensuring it remains at the forefront of diagnostic innovation.
DitchCarbon Score
How does Chembio Diagnostics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Chembio Diagnostics, Inc.'s score of 25 is lower than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Chembio Diagnostics, Inc.'s reported carbon emissions
Chembio Diagnostics, Inc., headquartered in the US, currently does not have specific carbon emissions data available, as indicated by the absence of reported figures. The company is a current subsidiary of Biosynex SA, which may influence its climate commitments and reporting practices. While Chembio has not set explicit reduction targets or initiatives, it is important to note that the broader industry context often drives companies to adopt sustainable practices. As a subsidiary, Chembio may align its climate strategies with those of its parent company, Biosynex SA, which could include participation in initiatives such as the Carbon Disclosure Project (CDP) at a cascade level of 1. In the absence of specific emissions data or reduction targets, Chembio Diagnostics, Inc. remains committed to exploring avenues for sustainability and may benefit from the climate strategies of its parent organisation.
How Carbon Intensive is Chembio Diagnostics, Inc.'s Industry?
How Carbon Intensive is Chembio Diagnostics, Inc.'s Location?
Chembio Diagnostics, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Chembio Diagnostics, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
